Corimmun, a Germany-based drug development company which spun off from the Universities of Würzburg and of Tübingen, has been sold to Janssen-Cilag, part of the Janssen Pharmaceutical Companies of US-based pharmaceutical group Johnson & Johnson.
Corimmun received €680,000 ($855,000) of funding in 2008 from High-Tech Gründerfonds, Bayern Kapital and BioM in 2007.
Corimmun’s main product is Cor-1, a peptide for the treatment of heart failure.
Corimmun was founded in 2006.
The University of Kentucky has formed an industry-university partnership to advance aspects such as sustainable agriculture in the whiskey distilling industry.
The £40m recently allocated by the UK government to proving university research is commercially viable shouldn't just benefit Oxford, Cambridge and London say sector pundits.
Global University Venturing (GUV) is where tech transfer, academic and investment experts meet to explore the latest ideas and technologies driving innovation forward. We drive the discussions and share best practices that are critical to the success of spinouts, scaleouts and innovation programmes. Our aim is to help improve the processes of bringing innovations from academia to global markets and facilitate their integration into the broader business ecosystem.
